Beam Therapeutics Inc. (BEAM) is a leading-edge biotechnology company that is involved in the development and commercialization of innovative gene therapies. The company's headquarters are located in Cambridge, Massachusetts, at the heart of one of the world's densest clusters of biotechnological innovations.
Established under the guidance of some of the most recognized leaders in the fields of molecular genetics and genomics, like David R. Liu, Feng Zhang, and J. Keith Joung, BEAM possesses the foundational CRISPR gene-editing patents. The company revolutionizes medicine with its commitment to developing gene therapies, that use base editing to treat serious illnesses.
BEAM's approach differs from conventional gene therapy, which can often have unintentional and potentially harmful consequences. The company's transformative base editing technology introduces precise, predictable, and controllable genetic changes at the molecular level. This involves changing the 'letters' of the DNA or RNA inside a cell to either correct a disease-causing error, or make a beneficial change. The proprietary base editing platforms are designed for high precision and enhanced safety.
Currently, BEAM's primary focus is on developing treatments for serious diseases such as sickle cell disease and beta-thalassemia that have limited therapeutic alternatives. Moreover, the company’s pipeline includes editing therapies for genetic and liver diseases, ocular diseases, and oncology.
Beam Therapeutics Inc., since its inception, has raised capital through an initial public offering (IPO) and private investments. The company debuted its IPO in February 2020 on the NASDAQ under the ticker BEAM, and it raised over $200 million.
BEAM continues to make advancements in genetic medicines utilizing one of the most advanced genomic editing technologies. With its strategic partnerships, skilled team, and robust financial standing, Beam Therapeutics is well-positioned to innovate and transform the genomic medicine landscape.